Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Milciclib · PHA-848125

Small molecule · Inhibitor of CDK2, CDK1 and CDK4 · developed by Tiziana Life Sciences

Phase 2 Most advanced trial (none active)
TLSA Developer
2 Registered trials

What is Milciclib?

Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDK1, CDK2, CDK4) and tropomyosin receptor kinase A (TRKA). It inhibits these kinases to induce cell cycle arrest and apoptosis in tumor cells. It is studied in hepatocellular carcinoma and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PHA-848125, PHA-848125AC
Drug type
Small molecule
Targets
CDK2, CDK1, CDK4, TRKA (NTRK1)
Mechanism
Inhibitor of CDK2, CDK1 and CDK4
Pathways
cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Tiziana Life Sciences LTD (TLSA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
688000M8S8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05651269 Phase 2 NSCLC Unknown TLSA
NCT03109886 Phase 2 Hepatocellular Carcinoma Completed TLSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular CarcinomaNSCLC

Other drugs acting on CDK2 / CDK1 / CDK4 / NTRK1

Abemaciclib FDA approved Repotrectinib FDA approved Atirmociclib Phase 1/2 Inixaciclib Phase 1/2

More from Tiziana Life Sciences

Foralumab Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TLSA page.

Follow TLSA, the company behind Milciclib

See TLSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TLSA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.